Lilly Beats on Q3 Earnings, Ups View, Mounjaro, Zepbound Drive Sales
Eli Lilly and Company LLY reported third-quarter 2025 adjusted earnings per share (“EPS”) of $7.02, which beat the Zacks Consensus Estimate of $6.02 per share. In the year-ago quarter, Lilly recorded earnings of $1.18 per share. Adjusted EPS included acquired IPR&D charges of 71 cents in the third quarter. Revenues of $17.60 billion rose 54% year […]
Weight-loss drugs may be slimming America faster than anyone expected
The obesity rate in the U.S. is continuing its downward trend. The news comes three years after obesity rates hit a record high. In 2022, almost four out of 10 (39.9%) of Americans met the threshold for the classification, however, the number first began to shrink in 2023. Now, the rate of obesity is now […]
US obesity rates drop in tandem with rising GLP-1 use | Morning in America
The rate of adult obesity in the United States continued its gradual decline in 2025, as the use of GLP-1 weight loss drugs saw a sharp incline, according to new polling from Gallup. NewsNation’s Anna Kooiman breaks down the numbers for “Morning in America.” #Health #Obesity #WeightLoss Start your day with “Morning in America,” NewsNation’s […]
American Obesity Rates Are Now Falling, and It’s Almost Certainly Because of Ozempic
For decades, the obesity rate among Americans trended inexorably higher, to a peak of 39.9 percent in 2022. But now, new data from Gallup’s National Health and Well-Being Index shows that something extraordinary has happened: that longstanding trend has reversed, with the obesity rate falling back down to 37 percent this year. “This is a […]
Competitive Landscape of Obesity Therapeutics Market Enters High-Growth Phase, Fueled by GLP-1 Surge and Expanding Oral Treatments | DataM Intelligence
AUSTIN, Texas and TOKYO, Oct. 30, 2025 /PRNewswire/ — According to DataM Intelligence, the obesity therapeutics market is on the cusp of major expansion. Although precise market size figures for this report were not publicly disclosed in full, broader indicators show the…
Mounjaro Powers Eli Lilly to Bumper Quarter of Earnings
Drugmaker’s shares jump after revenue from weight-loss drug more than doubles Eli LillyLLY-0.80%decrease; red down pointing triangle reported higher third-quarter profit and raised its full-year outlook on surging demand for its GLP-1 weight-loss drugs, sending its shares higher in premarket trading. …
Taking GLP-1s to Get Ahead at Work
Photo-Illustration: by The Cut; Photos: Getty Images It’s tough to put a dollar amount on the advantages of looking conventionally “attractive” (young, well-dressed, thin), but the professional upsides are uncomfortably clear, especially when it comes to weight. Decades of research shows that people who are thinner tend to make more money and attain higher-status jobs, […]
GNC Publishes Groundbreaking GLP-1 Supplement Review to Guide Clinicians to Support GLP-1 Consumers
PITTSBURGH, Pa., Oct. 30, 2025 /PRNewswire/ — GNC, the global leader in health and wellness, announced the publication of a new peer-reviewed journal article, “Dietary Supplement Considerations During Glucagon-like Peptide-1 Receptor Agonist Treatment: A Narrative Review,” in Obesity…
US weight-loss drugs drive drop in obesity levels
Obesity levels in the US are falling, driven by the increased use of GLP-1 weight-loss drugs such as Ozempic. The US has some of the highest obesity rates in the world, and the percentage of Americans with BMI over 30 — the classification for obesity — peaked at 39.9% in 2022, but has now fallen […]
Danone’s playbook in the GLP-1 arena: 3 key moves
Danone is expanding into GLP-1 nutrition with dairy, microbiome solutions, and plant-based shakes. Three key moves shaping its strategy.